Welcome to our dedicated page for Syra Health news (Ticker: SYRA), a resource for investors and traders seeking the latest updates and insights on Syra Health stock.
Syra Health Corp. reports news as an integrated healthcare solutions company serving government, public-sector, and commercial healthcare organizations. Its updates center on prevention-focused and access-oriented solutions, including Population Health programs, healthcare analytics, HIPAA-compliant digital health tools, health education, training, and healthcare workforce solutions.
Recurring company developments include quarterly and annual financial results, margin and profitability trends, Population Health revenue growth, customer demand from state health departments and private-sector organizations, and cost-management initiatives. Syra Health also reports governance and leadership changes, information-security milestones such as ISO 27001:2022 certification, and operating risks tied to government healthcare budgets and contract timing.
Syra Health (OTCQB: SYRA) announced an expanded partnership with Wake County Public Health in North Carolina through the launch of Wellness S.P.A. 2.0, an enhanced employee wellness program. The initiative follows a successful initial S.P.A. pilot focused on mental and emotional well-being of public health staff.
Wellness S.P.A. 2.0 will be delivered in three six-week cohorts, covering weekly topics such as stress and sleep hygiene, boundaries, productivity, conflict, and meaningful self-care. According to Syra Health, additional cohorts are planned for later 2026 and early 2027 in response to continued demand.
Syra Health (OTCQB: SYRA) reported its second consecutive profitable quarter in Q2 2026, with net income of $250,242 versus a net loss of $(63,596) a year earlier. Revenue rose 23% year-over-year to $2.39 million, driven by 8% growth in population health solutions to $1.72 million and an 87% increase in healthcare workforce revenue to $678,113. Gross margin improved to 44.5% from 38.7%, and EPS reached $0.02 compared with a loss of $(0.01).
EBITDA turned positive at $253,200 compared with a loss of $(53,760). For the first half of 2026, net income was $491,221 and operating cash flow was $643,183. Syra Health renewed key contracts, extended its Indiana FSSA engagement through October 2028, formed a Business Advisory Council, and reported $2.1 million in cash with no long-term debt, while reiterating its focus on full-year 2026 profitability and noting expected CMS ACCESS Model approval with partner HealthSync as a potential long-term revenue source.
Syra Health (OTCQB: SYRA) announced it will release its financial results for the three months ended June 30, 2026 on Tuesday, August 11, 2026. According to Syra Health, the second quarter 2026 results will be issued in a press release before the market opens, providing investors with performance details ahead of that trading day.
Syra Health (OTCQB: SYRA) appointed Dr. Cori McMahon, PsyD, NCCE as Chief Medical Officer in a fractional role to support its growth strategy. She will strengthen engagement with healthcare stakeholders and guide expansion across commercial and public sectors, focusing on behavioral and population health solutions.
Syra Health (OTCQB: SYRA) reported its first profitable quarter in Q1 2026, with net income $240,979 and EPS $0.02. Revenue was $2.3M, up 22% year-over-year, driven by population health $1.8M (+46% YoY). Gross margin expanded to 42.7% (up 11 percentage points). Cash grew to $2.9M and the company reported no long-term debt. Management noted milestone-driven quarterly variability but reiterated a goal of full-year profitability.
Syra Health (OTCQB: SYRA) will report first-quarter 2026 financial results for the period ended March 31, 2026, on Thursday, May 7, 2026. The company said the results will be released in a press release before the market opens.
Investors can expect the announcement via the company’s usual public channels on that date.
Syra Health (OTCQB: SYRA) won two 2026 TechPoint Mira Awards on April 28, 2026: the BioCrossroads Life Sciences Innovation Award for Syrenity and Innovation of the Year for its technology, including SyraBot and HIPAA-compliant platforms.
The recognition highlights early clinical impact for Syrenity, multi-state expansion plans, and independent validation from a 231-submission awards program judged by industry peers.
Syra Health (OTCQB: SYRA) announced a telehealth partnership with Nora Mental Health on April 2, 2026 to integrate licensed therapists into Syra's AI-driven Syrenity behavioral health app.
The collaboration creates referral pathways from Syrenity's risk stratification to Nora's telehealth or in-person care and includes joint clinical evaluation and HIPAA-compliant data practices.
Syra Health (SYRA) reported strong FY2025 results: population health revenue grew 157% to $5.3M and net loss narrowed 76% to ($896K) from ($3.8M). EPS improved to ($0.08) from ($0.50). Operating expenses declined 37% to $3.4M and gross margin rose to 34.4% from 20.7%.
The company ended 2025 with $1.6M cash, no long-term debt, launched new contracts and pilots, submitted Syrenity to FDA TEMPO, and expects profitability by year-end 2026.
Syra Health (OTCQB: SYRA) will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. The company said it will release results via a press release before the market opens. Investors should monitor filings and the company website for the release.